Key Takeaways:
Goldman Sachs has reaffirmed its confidence in Eli Lilly (NYSE: LLY), maintaining a "Buy" rating and issuing a new price target of $1260 per share.
The investment bank's optimism is rooted in the anticipated early approval of Eli Lilly's oral weight-loss drug, which it believes will kickstart a significant new product cycle, according to the report released on April 2.
The upgrade from a major Wall Street firm underscores the immense market potential seen in the obesity drug sector. Eli Lilly is in a heated race with competitors like Novo Nordisk to capture share in a market estimated to be worth billions. The potential for an effective oral alternative to existing injectable treatments is seen as a major catalyst for growth.
The new price target suggests a strong conviction in Eli Lilly's pipeline and its ability to execute on this new product cycle. Investors will be closely watching for any announcements from the US Food and Drug Administration (FDA) regarding the approval timeline for the oral drug.
This article is for informational purposes only and does not constitute investment advice.
